Shalby Limited — PPTs, 04-02-2025: Investor Presentation

**Financial Highlights:**

Consolidated revenue reached ₹2,811 million in Q3 FY25, up 27.4% from ₹2,206 million in Q3 FY24. However, consolidated EBITDA fell to ₹393 million, down 16.1% year-over-year. Profit before tax (PBT) also showed a decline to ₹124 million, a 59.9% drop compared to ₹308 million in Q3 FY24. Standalone revenue stood at ₹2,269 million, marking a 13.3% increase, with EBITDA slightly up at ₹488 million. Standalone PBT decreased to ₹358 million, a reduction of 7% from the previous year, while net cash on the balance sheet was ₹660 million at the end of December 2024.

**Strategic Initiatives and Growth Drivers:**

Shalby is advancing its growth strategy by expanding its footprint with plans to open 40 Orthopedic franchises across India. The company continues to lead in joint replacements, with ongoing diversification into cardiac, oncological, and neurological specialties.

**Business Developments:**

The launch of the franchise model aims to tap into new markets while maintaining operational standards. Shalby Homecare services experienced a 5.5% increase in patients served, highlighting growth in the home healthcare segment.

**Market Position and Competitive Advantage:**

Shalby remains the largest corporate hospital group in Western and Central India, leveraging its integrated healthcare model to offer comprehensive services.

**Investor Implications:**

Despite mixed financial performance, Shalby’s diversified service offerings and expansion plans present a positive outlook for future growth, making it a potential beneficiary in the evolving healthcare landscape. Investors should monitor its ability to leverage growth in new specialties and maintain operational efficiency.